Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 16/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 16/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407431 | 0.93 | NR1H2 (0.40) | NR1H2NR1H3ESR1RXRAKCNH2 | |
| SCHEMBL1408292 | 0.92 | LMNA (0.42) | NR1H2NR1H3LMNAESR1RXRA | |
| SCHEMBL3863786 | 0.86 | NR1H2 (0.44) | NR1H2NR1H3RXRA | |
| SCHEMBL1407691 | 0.85 | NR1H3 (0.39) | NR1H2NR1H3LMNAESR1RXRA | |
| SCHEMBL3865607 | 0.80 | NR1H2 (0.42) | NR1H2NR1H3RXRA | |
| SCHEMBL3860076 | 0.79 | NR1H2 (0.43) | NR1H2NR1H3LMNARXRA | |
| SCHEMBL1407778 | 0.73 | NR1H3 (0.42) | NR1H2NR1H3RXRA | |
| SCHEMBL1408496 | 0.73 | NR1H2 (0.42) | NR1H2NR1H3LMNARXRA | |
| SCHEMBL3858575 | 0.73 | NR1H3 (0.43) | NR1H2NR1H3RXRA | |
| SCHEMBL1407098 | 0.72 | LMNA (0.43) | NR1H2NR1H3LMNARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2295429-A1 | 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7592363-B2 | Indazoles | WYETH (US) | 2009-09-22 | — | — | US | disclosed |
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | NR1H2, NR1H3, CYP46A1 | NR1H2 1/4885NR1H3 2/4885LMNA 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.